Pilot Study of Interpersonal Psychotherapy Versus Supportive Psychotherapy for Dysthymic Patients With Secondary Alcohol Abuse or Dependence
Department of Psychiatry, Weill Medical College of Cornell University, New York, New York 10032, USA. The Journal of nervous and mental disease
(Impact Factor: 1.69).
07/2008; 196(6):468-74. DOI: 10.1097/NMD.0b013e31817738f1
Interpersonal psychotherapy (IPT) has demonstrated efficacy for depression but yielded negative results for substance disorders. Alcohol abuse frequently complicates mood disorders. This pilot study compared IPT with brief supportive psychotherapy (BSP) for dysthymic disorder and alcohol abuse. We hypothesized that effect sizes would suggest greater IPT efficacy for both diagnoses, despite limited statistical power. Subjects with primary DSM-IV dysthymic disorder and secondary alcohol abuse/dependence were randomly assigned 16 weeks of IPT (N = 14) or BSP (N = 12). Patients in both treatments reported improved depressive symptoms and alcohol abstinence. IPT had a large and BSP a moderate effect size in depression, whereas BSP had a moderate and IPT a small effect size in percentage of days abstinent. This pilot study offers initial data on IPT and BSP for comorbid chronic depression and alcohol abuse/dependence. Results suggest IPT may have specific antidepressant benefits for dysthymic alcoholic patients but not in treating alcoholism.
Available from: Aaron Jason Fisher
- "For BSP, the expectation of an alliance– outcome association is consistent with the model's putative focus on " common factors, " including the therapeutic alliance (Markowitz, Manber, & Rosen, 2008). As Markowitz et al. (2008) noted, although all psychotherapies use common factors, " they . . . do so to differing degrees " (p. "
[Show abstract] [Hide abstract]
This study tested whether the quality of the patient-rated working alliance, measured early in treatment, predicted subsequent symptom reduction in chronically depressed patients. Secondarily, the study assessed whether the relationship between early alliance and response to treatment differed between patients receiving cognitive behavioral analysis system of psychotherapy (CBASP) vs. brief supportive psychotherapy (BSP).
395 adults (57% female; Mage = 46; 91% Caucasian) who met criteria for chronic depression and did not fully remit during a 12-week algorithm-based, open-label pharmacotherapy trial were randomized to receive either 16-20 sessions of CBASP or BSP in addition to continued, algorithm-based antidepressant medication. Of these, 224 patients completed the Working Alliance Inventory-Short Form at Weeks 2 or 4 of treatment. Blind raters assessed depressive symptoms at 2-week intervals across treatment using the Hamilton Rating Scale for Depression. Linear mixed models tested the association between early alliance and subsequent symptom ratings while accounting for early symptom change.
A more positive early working alliance was associated with lower subsequent symptom ratings in both the CBASP and BSP, F(1, 1236) = 62.48, p < .001. In addition, the interaction between alliance and psychotherapy type was significant, such that alliance quality was more strongly associated with symptom ratings among those in the CBASP treatment group, F(1, 1234) = 8.31, p = .004.
The results support the role of the therapeutic alliance as a predictor of outcome across dissimilar treatments for chronic depression. Contrary to expectations, the therapeutic alliance was more strongly related to outcome in CBASP, the more directive of the 2 therapies.
Journal of Consulting and Clinical Psychology 01/2013; 81(4). DOI:10.1037/a0031530 · 4.85 Impact Factor
Available from: Jennifer Johnson
- "IPT is an evidence-based treatment with proven effectiveness for MDD in non-criminal justice settings in both individual and group formats (Bolton et al., 2003; Elkin et al., 1989; Frank and Spanier, 1995; Frank et al., 1991; Levkovitz et al., 2000; Rossello et al., 2008; Shea et al., 1992). Studies to date have not found IPT to be superior to other treatments as a standalone substance use disorder treatment (Carroll et al., 1991, 2004; Markowitz et al., 2008; Rounsaville et al., 1983, 1986b). However, these studies included few female subjects, few subjects with MDD, and little or no concurrent substance use treatment. "
[Show abstract] [Hide abstract]
ABSTRACT: This study, the largest randomized controlled trial of treatment for major depressive disorder (MDD) in an incarcerated population to date, wave-randomized 38 incarcerated women (6 waves) with MDD who were attending prison substance use treatment to adjunctive group interpersonal psychotherapy (IPT) for MDD or to an attention-matched control condition. Intent-to-treat analyses found that IPT participants had significantly lower depressive symptoms at the end of 8 weeks of in-prison treatment than did control participants. Control participants improved later, after prison release. IPT's rapid effect on MDD within prison may reduce serious in-prison consequences of MDD.
Journal of Psychiatric Research 06/2012; 46(9):1174-83. DOI:10.1016/j.jpsychires.2012.05.007 · 3.96 Impact Factor
Available from: Morten Hesse
- "Four studies reported self-report questionnaire outcomes for depression [11,12,14,15]. The combined effect was d = -0.58 "
[Show abstract] [Hide abstract]
ABSTRACT: There is an increasing consensus in favour of integrated treatment of substance use disorders and co-morbid conditions, such as depression or anxiety. However, up till now no systematic reviews have been published.
Based on a systematic search of MedLine and PsychInfo, 9 trials of integrated treatment for depression or anxiety plus substance use disorder were identified. Where possible, meta-analyses were carried out, using random effects models.
Meta-analyses were carried out for integrated treatment for depression and substance use disorders on a number of outcomes. No meta-analysis could be carried out for integrated treatment for anxiety and substance use disorders, due to multivariate reporting of outcomes in original articles. Integrated treatment for depression and substance abuse produced significant effects on percent days abstinent at follow-up. Differences in retention and symptoms were non-significant, but favoured the experimental condition. For studies of integrated treatment for co-morbid anxiety disorders and substance use disorders, no meta-analysis could be carried out. Several studies of integrated treatment for anxiety and substance use disorders reported that patients assigned to substance use treatment only fared better.
Psychotherapeutic treatment for co-morbid depression and substance use disorders is a promising approach, but is not sufficiently empirically supported at this point. Psychotherapeutic treatment for co-morbid anxiety and substance use disorders is not empirically supported. There is a need for more trials to replicate the findings from studies of integrated treatment for depression and substance use disorders, and for the development of new treatment options for co-morbid anxiety and substance use disorders.
BMC Psychiatry 03/2009; 9(1):6. DOI:10.1186/1471-244X-9-6 · 2.21 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.